Blinatumomab: Interim Phase I data

Data from 12 patients with indolent follicular lymphoma or mantle cell lymphoma in an open-label Phase I trial showed that 60 µg/m 2/day blinatumomab produced 4 complete responses and 7 partial responses, as measured by the 1996 National Cancer Institute Working Group (NCIWG) criteria, with a median duration of 12 months as of July. The non-responding patient experienced a neurological adverse event leading to early discontinuation of treatment. The most frequent grade 3/4 adverse event was lymphopenia seen in 77% of patients. ...